drugset / Trial / NCT04484675

Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension

NCT04484675

Phase 4 Recruiting 38 enrolled Zagazig University
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The investigator compared difference between inhaled and intravenous milirinone in patiens with severe pulmonary hypertension undergoing cardiac surgery

Timeline

Start
2023-05-20
Primary completion
2025-05-10
Completion
2025-05-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Milrinone Small molecule 0.5 ug/kg Inhaled
Comparator Milrinone Small molecule 1 mg/ml Inhaled